FDA accepts Corcept's new drug application for ovarian cancer treatment

Corcept Therapeutics (CORT) announced the FDA's acceptance of its New Drug Application for relacorilant, a treatment for platinum-resistant ovarian cancer, setting a PDUFA date of July 11, 2026. This development, based on positive Phase 3 and 2 clinical trial data showing improved patient survival, is a significant step towards addressing a critical unmet medical need and follows a 104%+ surge in CORT's stock over the past year. While the company maintains a strong financial position, its recent Q2 2025 earnings reported an EPS beat alongside a slight revenue miss, attributed to ongoing supply chain challenges, presenting a mixed operational picture despite pipeline progress.

Analysis

Corcept Therapeutics (CORT) has achieved a significant regulatory milestone with the U.S. FDA's acceptance of its New Drug Application (NDA) for relacorilant in treating platinum-resistant ovarian cancer. This decision, which sets a PDUFA date of July 11, 2026, validates the drug's potential based on Phase 3 ROSELLA trial data showing improved progression-free and overall survival. The potential market is notable, targeting approximately 20,000 U.S. women annually, with the added advantage of not requiring biomarker selection. This pipeline progress is a primary factor behind the stock's over 104% surge in the past year, pushing its valuation to $7.56 billion. However, recent operational performance presents a more complex picture. In its Q2 2025 results, the company reported a strong earnings per share of $0.29, beating forecasts by 52.63%, but missed revenue expectations by 2.51% with $194.4 million reported. This revenue shortfall is attributed to ongoing supply chain challenges, highlighting a near-term operational headwind that contrasts with the company's long-term clinical development success and strong financial position, which is underscored by a current ratio of 3.06 and minimal debt.

Key Decisions for Investors

• Given the distant PDUFA date of July 2026 for relacorilant, investors should weigh the long-term catalyst of a potential new therapy against the multi-year timeline to commercialization.
• Monitor subsequent quarterly earnings for resolution of the supply chain issues that caused the Q2 revenue miss, as persistent operational headwinds could impact near-term performance despite pipeline advancements.
• Considering the stock has already appreciated over 104% in the last year and trades near its fair value estimate, new investors should be mindful that much of the positive regulatory news may already be priced into the current valuation.